Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Cys6.0

Cysteamin (topisch) – Forschung

Überwiegend Mechanismus / Beobachtung

13 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Cysteamin (topisch) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2015–2025 mit einer typischen Studiengröße von 65 Teilnehmenden.

Basierend auf 13 Studien · 2 Meta-Analysen · 8 RCTs · 105 Teilnehmende insgesamt

Konfidenz

Hohe Konfidenz

Nach Outcome

Skin tone & pigmentationDeutliche Reduktion von Melasma gegenüber Placebo; eine Hydrochinon-freie Alternative (bestenfalls etwa gleichwertig mit HQ) · 8-16 Wochen
Überwiegend Mechanismus / Beobachtung12 Studien
Safety profile
Zu wenige bewertete Studien2 Studien

Aktives Forschungsgebiet

10 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024

201520202025

1Meta-Analyse2022

Dos Santos-Neto AG, da Silva ÍCV, Melo CR, Santana AAM, de Albuquerque-Junior RLC · Dermatol Ther (2022)

Quelle ansehen

2Systematische Übersicht2021

Ahramiyanpour N, Saki N, Akbari Z, Shamsi-Meymandi S, Amiri R, Heiran A · J Cosmet Dermatol (2021)

Quelle ansehen

3Systematische Übersicht2025

Kusumawardani A, Octarica SG, Dewi AK, Sambodo SL, Utama RFD, Adjie SP · Acta Dermatovenerol Alp Pannonica Adriat (2025)

4RCT2025

Tsai YW, Lin JH, Lai YJ, Liu TL, Ng CY · J Cosmet Dermatol (2025)

Quelle ansehen

5RCT2018

Farshi S, Mansouri P, Kasraee B · J Dermatolog Treat (2018)

Quelle ansehen

6RCT2025

Kusumawardani A, Murasmita A, Rosmarwati E, Norawati Ashadi L, Setiawan SV, Murlistyarini S · Acta Dermatovenerol Alp Pannonica Adriat (2025)

7RCT2015

Mansouri P, Farshi S, Hashemi Z, Kasraee B · Br J Dermatol (2015)

Quelle ansehen

8RCT2024

Sachdev M, Grimes PE, Callender V, Hartman CL, Taylor SC, Elbuluk N · J Drugs Dermatol (2024)

Quelle ansehen

9RCT2021

Karrabi M, David J, Sahebkar M · Skin Res Technol (2021)

Quelle ansehen

10Meta-Analyse2024

Einfach gesagt: Cysteamine 5% was more effective than placebo in reducing the Melasma Area and Severity Index (SMD - 0.84; 95% CI - 1.19, - 0.49, p < 0.00001, I2 = 0%), but showed no significant difference when compared with hydroquinone 4% (SMD 0.16; 95% CI - 0.22, 0.53, p = 0.42).

Mawu FO, Christopher PM. · Arch Dermatol Res (2024)

RCT-only meta-analysis of 7 trials comparing cysteamine 5% with placebo or hydroquinone
Significantly more effective than placebo (SMD -0.84, I²=0%), but no significant difference vs hydroquinone 4% (non-superiority)
Adverse events higher than placebo but similar to hydroquinone — a comparable, not superior, alternative

Quelle ansehen

11RCTn=40 · small study2020

Einfach gesagt: Cysteamine proved to be safe, well-tolerated, and effective, despite its inferior performance to hydroquinone in decreasing mMASI and MELASQoL in the treatment of melasma.

Lima PB, Dias JAF, Cassiano D, Esposito ACC, Bagatin E, Miot LDB, Miot HA. · Int J Dermatol (2020)

Multicenter evaluator-blinded head-to-head of cysteamine 5% vs hydroquinone 4% (n=40), nightly for 120 days with sunscreen
Hydroquinone outperformed cysteamine on mMASI (53% vs 38% reduction, P=0.017) and on quality of life
Erythema and burning were the most notable cysteamine adverse effects — the key counter-evidence (cysteamine inferior to HQ)

Quelle ansehen

12RCTn=65 · small study2022

Einfach gesagt: Cysteamine was confirmed to be an effective treatment for melasma, with equivalent results to HC in reducing mMASI score and improving quality of life, despite lesser melanin index reduction observed.

Sepaskhah M, Karimi F, Bagheri Z, Kasraee B. · J Cosmet Dermatol (2022)

Single-blind RCT (n=65 completers) comparing cysteamine 5% vs hydroquinone 4%/ascorbic acid 3% over 4 months
Both significantly reduced mMASI with no significant between-group difference
But the hydroquinone combination produced a significantly greater melanin-index reduction (p=0.002)

Quelle ansehen

13In vitro2021

Einfach gesagt: L-cysteinamide at certain concentrations can inhibit eumelanin synthesis through a dual mechanism by inhibiting TYR-catalyzed dopaquinone synthesis and by diverting the synthesized dopaquinone to the formation of DOPA-cysteinamide conjugates rather than dopachrome.

Lee HK, Ha JW, Hwang YJ, Boo YC. · Antioxidants (Basel) (2021)

In-vitro study comparing thiol compounds (including cysteamine) against tyrosinase-mediated dopachrome formation and melanin in melanoma cells/melanocytes
Demonstrates the shared aminothiol mechanism: inhibiting tyrosinase-catalyzed dopaquinone synthesis plus diverting dopaquinone into thiol conjugates, lowering total melanin
Supports the mechanistic class (cysteamine tested as a thiol comparator); in-vitro only

Quelle ansehen

In der Forschungsbibliothek ansehen

Cysteamin (topisch) – Forschung

Überwiegend Mechanismus / Beobachtung

Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis.

Efficacy of topical cysteamine hydrochloride in treating melasma: a systematic review.

The efficacy of cysteamine as a melasma therapy: a systematic review of trial studies.

Efficacy and Safety of Combination Therapy of Microneedling Radiofrequency, In-Office and Home-Based Topical Cysteamine in Refractory Melasma: A Split Face, Vehicle-Control, Randomized Control Trial.

Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study.

Efficacy of overnight leave-on sandwich therapy with 5% cysteamine and ectoine cream compared to hydroquinone 4% cream for treatment of melasma: a double-blind randomized controlled trial.

Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial.

Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action.

Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study.

Efficacy and safety of cysteamine 5% cream for the management of melasma: a systematic review and meta-analysis of randomized controlled trials.

A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.

Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.

Identification of L-Cysteinamide as a Potent Inhibitor of Tyrosinase-Mediated Dopachrome Formation and Eumelanin Synthesis.